Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.77 |
---|---|
High | 26.17 |
Low | 25.05 |
Bid | 25.05 |
Offer | 25.28 |
Previous close | 25.78 |
Average volume | 210.98k |
---|---|
Shares outstanding | 27.50m |
Free float | 26.73m |
P/E (TTM) | -- |
Market cap | 708.86m USD |
EPS (TTM) | -9.45 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 17:10 BST.
More ▼
Announcements
- LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
- LENZ Therapeutics to Participate in Upcoming Investor Conferences
- LENZ Therapeutics Reports Second Quarter 2024 Financial Results
- LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
- LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
- LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
- LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
- LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
More ▼